Cargando…
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the effect of dapagliflozin on markers of iron metabolism. We als...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508991/ https://www.ncbi.nlm.nih.gov/pubmed/35971840 http://dx.doi.org/10.1161/CIRCULATIONAHA.122.060511 |
_version_ | 1784797137398136832 |
---|---|
author | Docherty, Kieran F. Welsh, Paul Verma, Subodh De Boer, Rudolf A. O’Meara, Eileen Bengtsson, Olof Køber, Lars Kosiborod, Mikhail N. Hammarstedt, Ann Langkilde, Anna Maria Lindholm, Daniel Little, Dustin J. Sjöstrand, Mikaela Martinez, Felipe A. Ponikowski, Piotr Sabatine, Marc S. Morrow, David A. Schou, Morten Solomon, Scott D. Sattar, Naveed Jhund, Pardeep S. McMurray, John J.V. |
author_facet | Docherty, Kieran F. Welsh, Paul Verma, Subodh De Boer, Rudolf A. O’Meara, Eileen Bengtsson, Olof Køber, Lars Kosiborod, Mikhail N. Hammarstedt, Ann Langkilde, Anna Maria Lindholm, Daniel Little, Dustin J. Sjöstrand, Mikaela Martinez, Felipe A. Ponikowski, Piotr Sabatine, Marc S. Morrow, David A. Schou, Morten Solomon, Scott D. Sattar, Naveed Jhund, Pardeep S. McMurray, John J.V. |
author_sort | Docherty, Kieran F. |
collection | PubMed |
description | Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the effect of dapagliflozin on markers of iron metabolism. We also analyzed the effect of dapagliflozin on outcomes, according to iron status at baseline. METHODS: Iron deficiency was defined as a ferritin level <100 ng/mL or a transferrin saturation <20% and a ferritin level 100 to 299 ng/mL. Additional biomarkers of iron metabolism, including soluble transferrin receptor, erythropoietin, and hepcidin were measured at baseline and 12 months after randomization. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death. RESULTS: Of the 4744 patients randomized in DAPA-HF, 3009 had ferritin and transferrin saturation measurements available at baseline, and 1314 of these participants (43.7%) were iron deficient. The rate of the primary outcome was higher in patients with iron deficiency (16.6 per 100 person-years) compared with those without (10.4 per 100 person-years; P<0.0001). The effect of dapagliflozin on the primary outcome was consistent in iron-deficient compared with iron-replete patients (hazard ratio, 0.74 [95% CI, 0.58–0.92] versus 0.81 [95% CI, 0.63–1.03]; P-interaction=0.59). Similar findings were observed for cardiovascular death, heart failure hospitalization, and all-cause mortality. Transferrin saturation, ferritin, and hepcidin were reduced and total iron-binding capacity and soluble transferrin receptor increased with dapagliflozin compared with placebo. CONCLUSIONS: Iron deficiency was common in DAPA-HF and associated with worse outcomes. Dapagliflozin appeared to increase iron use but improved outcomes, irrespective of iron status at baseline. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124. |
format | Online Article Text |
id | pubmed-9508991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95089912022-10-03 Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF Docherty, Kieran F. Welsh, Paul Verma, Subodh De Boer, Rudolf A. O’Meara, Eileen Bengtsson, Olof Køber, Lars Kosiborod, Mikhail N. Hammarstedt, Ann Langkilde, Anna Maria Lindholm, Daniel Little, Dustin J. Sjöstrand, Mikaela Martinez, Felipe A. Ponikowski, Piotr Sabatine, Marc S. Morrow, David A. Schou, Morten Solomon, Scott D. Sattar, Naveed Jhund, Pardeep S. McMurray, John J.V. Circulation Original Research Articles Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the effect of dapagliflozin on markers of iron metabolism. We also analyzed the effect of dapagliflozin on outcomes, according to iron status at baseline. METHODS: Iron deficiency was defined as a ferritin level <100 ng/mL or a transferrin saturation <20% and a ferritin level 100 to 299 ng/mL. Additional biomarkers of iron metabolism, including soluble transferrin receptor, erythropoietin, and hepcidin were measured at baseline and 12 months after randomization. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death. RESULTS: Of the 4744 patients randomized in DAPA-HF, 3009 had ferritin and transferrin saturation measurements available at baseline, and 1314 of these participants (43.7%) were iron deficient. The rate of the primary outcome was higher in patients with iron deficiency (16.6 per 100 person-years) compared with those without (10.4 per 100 person-years; P<0.0001). The effect of dapagliflozin on the primary outcome was consistent in iron-deficient compared with iron-replete patients (hazard ratio, 0.74 [95% CI, 0.58–0.92] versus 0.81 [95% CI, 0.63–1.03]; P-interaction=0.59). Similar findings were observed for cardiovascular death, heart failure hospitalization, and all-cause mortality. Transferrin saturation, ferritin, and hepcidin were reduced and total iron-binding capacity and soluble transferrin receptor increased with dapagliflozin compared with placebo. CONCLUSIONS: Iron deficiency was common in DAPA-HF and associated with worse outcomes. Dapagliflozin appeared to increase iron use but improved outcomes, irrespective of iron status at baseline. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124. Lippincott Williams & Wilkins 2022-08-16 2022-09-27 /pmc/articles/PMC9508991/ /pubmed/35971840 http://dx.doi.org/10.1161/CIRCULATIONAHA.122.060511 Text en © 2022 The Authors. https://creativecommons.org/licenses/by/4.0/Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited. |
spellingShingle | Original Research Articles Docherty, Kieran F. Welsh, Paul Verma, Subodh De Boer, Rudolf A. O’Meara, Eileen Bengtsson, Olof Køber, Lars Kosiborod, Mikhail N. Hammarstedt, Ann Langkilde, Anna Maria Lindholm, Daniel Little, Dustin J. Sjöstrand, Mikaela Martinez, Felipe A. Ponikowski, Piotr Sabatine, Marc S. Morrow, David A. Schou, Morten Solomon, Scott D. Sattar, Naveed Jhund, Pardeep S. McMurray, John J.V. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF |
title | Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF |
title_full | Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF |
title_fullStr | Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF |
title_full_unstemmed | Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF |
title_short | Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF |
title_sort | iron deficiency in heart failure and effect of dapagliflozin: findings from dapa-hf |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508991/ https://www.ncbi.nlm.nih.gov/pubmed/35971840 http://dx.doi.org/10.1161/CIRCULATIONAHA.122.060511 |
work_keys_str_mv | AT dochertykieranf irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT welshpaul irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT vermasubodh irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT deboerrudolfa irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT omearaeileen irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT bengtssonolof irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT køberlars irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT kosiborodmikhailn irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT hammarstedtann irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT langkildeannamaria irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT lindholmdaniel irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT littledustinj irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT sjostrandmikaela irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT martinezfelipea irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT ponikowskipiotr irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT sabatinemarcs irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT morrowdavida irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT schoumorten irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT solomonscottd irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT sattarnaveed irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT jhundpardeeps irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf AT mcmurrayjohnjv irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf |